Paul Chaney , O
United States of America
Paul Chaney is president and CEO of PanOptica and has nearly 30 years of experience in the pharmaceutical industry. He was responsible for Xalatan, the most widely prescribed treatment for elevated intraocular pressure (glaucoma) and the first pharmacotherapy for neovascular AMD. Prior to co-founding PanOptica, Paul was executive vice president of OSI Pharmaceuticals and president of (OSI) Eyetech, OSI’s eyecare subsidiary. He joined Eyetech Pharmaceuticals as chief operating officer in 2003. Paul held a variety of senior management positions at Pharmacia Corporation, including vice president of the Global Ophthalmology Business and vice president of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.